Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
22 Junio 2023 - 3:05PM
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage,
oncology-focused biopharmaceutical company developing proprietary
antibody-based therapeutics to treat multiple human diseases, today
announced that it will be added to the Russell
2000
® and Russell 3000
® Indexes
as part of the Russell indexes annual reconstitution, effective
after the US market opens on June 26, 2023.
Membership in the US all-cap Russell 3000®
Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or
small-cap Russell 2000® Index as well as
membership and inclusion in the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings, and style
attributes.
“We are pleased to be added to the Russell Indexes,” said Vered
Bisker-Leib, President & COO of Compass Therapeutics. “The
inclusion of Compass will enhance trading activity of our stock and
broaden our exposure to the investment community, which may help
accelerate our efforts to develop next generation antibodies into
transformative cancer therapies that improve patients’ lives.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $12 trillion in assets
are benchmarked against Russell’s US indexes. Russell indexes are
part of FTSE Russell, a leading global index provider.
For more information about the Russell U.S. Indexes and the
Russell index reconstitutions, visit the FTSE Russell website.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused
biopharmaceutical company developing proprietary antibody-based
therapeutics to treat multiple human diseases. Compass’s scientific
focus is on the relationship between angiogenesis, the immune
system, and tumor growth. The company pipeline of novel product
candidates is designed to target multiple critical biological
pathways required for an effective anti-tumor response. These
include modulation of the microvasculature via
angiogenesis-targeted agents, induction of a potent immune response
via activators on effector cells in the tumor microenvironment, and
alleviation of immunosuppressive mechanisms used by tumors to evade
immune surveillance. Compass plans to advance its product
candidates through clinical development as both standalone
therapies and in combination with proprietary pipeline antibodies
based on supportive clinical and nonclinical data. The company was
founded in 2014 and is headquartered in Boston, Massachusetts. For
more information, visit the Compass Therapeutics website
at https://www.compasstherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to Compass’s financial
position, potential trading and investment activities, and
statements regarding Compass’s product candidates and the
development thereof. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, Compass’s ability to
raise the additional funding it will need to continue to pursue its
business and product development plans, the inherent uncertainties
associated with developing product candidates and operating as a
development stage company, Compass’s ability to identify additional
product candidates for development, Compass’s ability to develop,
complete clinical trials for, obtain approvals for and
commercialize any of its product candidates, competition in the
industry in which Compass operates and market conditions. These
forward-looking statements are made as of the date of this press
release, and Compass assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all
of the information set forth herein and should also refer to the
risk factor disclosure set forth in the reports and other documents
Compass files with the SEC available at www.sec.gov, including
without limitation Compass’s latest Form 10-Q and subsequent
filings with the SEC.
Investor Contactir@compasstherapeutics.com
Media Contact Anna Gifford, Communications
Manager media@compasstherapeutics.com617-500-8099
Compass Therapeutics (NASDAQ:CMPX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Compass Therapeutics (NASDAQ:CMPX)
Gráfica de Acción Histórica
De May 2023 a May 2024